Diabetic nephropathy syndrome
Conditions
Interventions
test group:Indobufen tablets
Sponsors
China-Japan Friendship Hospital Clinical Research Ethics Committee
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. 2015 ADA Diabetes Medical Treatment Criteria (Type 2): Fasting plasma glucose (FPG) =7.0 mmol/L, or Symptoms + Randomized blood glucose =11.1 mmol/L; 3. In line with the main criteria for the diagnosis of nephrotic syndrome: 24 hours urinary protein quantification = 3.5g, and plasma albumin less than 30g/L, and> 20g/L; 4. Patients with hypercoagulable conditions requiring indobufen or clopidogrel bisulfate to prevent DVT; 5. Sign the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: 1. Previous patients with an allergy to indobufen or clopidogrel hydrogen sulfate; 2. Patients diagnosed with embolism by B-mode ultrasound, CT, magnetic resonance tomography (MR), and pulmonary ventilation perfusion scintigraphy, or unexplained D-dimer doubling, up to 2 times the upper limit of the reference value; 3. Coagulation disorders exist; 4. Patients with uncontrolled hypertension have diastolic blood pressure> 100 mmHg; 5. Patients with severe hepatic and renal impairment; 6. Patients with bleeding risk, active ulcers or history of gastrointestinal bleeding; 7. Patients who are taking other drugs that may affect the outcome of clinical trials; 8. Pregnant women; 9. unable to complete the follow-up due to their own conditions and other reasons; 10. merged with cancer, severe heart failure, etc .; 11. Participate in any drug test within the first 3 months of enrollment; Any other diseases that the researchers think are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| D-dimer;Doppler ultrasound;Thromboembolic event rate; | — |
Countries
China
Contacts
Public ContactLi Wenge
China-Japan Friendship Hospital
Outcome results
None listed